TY - JOUR
T1 - Potential deprescribing indications for antidepressants between 2012 and 2019
T2 - repeated cross-sectional analysis in two Scottish health boards
AU - Brisnik, Vita
AU - Rottenkolber, Marietta
AU - Vukas, Jochen
AU - Schechner, Miriam
AU - Lukaschek, Karoline
AU - Jung-Sievers, Caroline
AU - Gensichen, Jochen
AU - Thiem, Ulrich
AU - Drey, Michael
AU - Krüger, Nils
AU - Mair, Alpana
AU - Guthrie, Bruce
AU - Fischer, Sebastian
AU - Dreischulte, Tobias
AU - POKAL Study Group
A2 - Falkai, Peter
A2 - Henningsen, Peter
A2 - Bühner, Markus
A2 - Krcmar, Helmut
A2 - Pitschel-Walz, Gabriele
A2 - Schneider, Antonius
A2 - Lochbuhler, Kirsten
A2 - Prommegger, Barbara
A2 - Schmitt, Andreas
A2 - Biersack, Katharina
A2 - Brand, Constantin
A2 - Ebert, Christopher
A2 - Eder, Julia
A2 - Gökce, Feyza
A2 - Haas, Carolin
A2 - Pfeiffer, Lisa
A2 - Kaupe, Lukas
A2 - Raub, Jonas
A2 - Reindl-Spanner, Philipp
A2 - Schillok, Hannah
A2 - Schönweger, Petra
A2 - Teusen, Clara
A2 - Vogel, Marie
A2 - von Schrottenberg, Victoria
A2 - Younesi, Puya
N1 - Publisher Copyright:
© The Author(s) 2024.
Data were obtained from a large, population-based data
set from Scotland provided by the University of Dundee/
National Health Service (NHS) Tayside Health Informatics Centre
PY - 2024/9/11
Y1 - 2024/9/11
N2 - Background: Antidepressants have a pivotal role in the treatment of many psychiatric disorders, but there are concerns about long-term use and adverse effects. The objectives of this study were (1) to examine time trends in antidepressant use, (2) to estimate the prevalence of long-term and potential high-risk antidepressant use, and (3) to examine patient characteristics associated with potential deprescribing indications (PDIs) (i.e., simultaneous long-term and potential high-risk antidepressant use). Methods: Repeated population-based cross-sectional study for all 609,299 people aged ≥ 18 years resident in the Tayside or Fife regions of Scotland. The prevalence of antidepressant use was examined on June 30th (index date) of each year from 2012 to 2019, while the prevalence of long-term and potential high-risk use as well as PDIs was assessed and compared on the same dates in 2012 and 2019. Binary logistic regression modeling was used to examine patient characteristics associated with PDIs. Results: Antidepressant use increased by 27% from 12.0 to 15.3% among adult residents between 2012 and 2019. While the proportion of antidepressants users dispensed ≥ 1 antidepressant for > 2 years increased from 54.3 to 61.9% between 2012 and 2019, the proportion of antidepressant users triggering ≥ 1 indicator of potential high-risk use decreased slightly from 37.9 to 34.7%. In 2019, potential high-risk use most commonly related to indicators targeting fall risk (16.0%), cardiovascular risks (14.1%), insomnia (10.6%), and risk of orthostatic hypotension (8.6%). More than 1 in 4 (25.8%) antidepressant users had PDIs. The main risk factors associated with PDIs included increasing age (65–79, adjusted OR 14.12; 95% CI, 13.15–15.17), increasing number of drugs taken concomitantly (≥ 15 drugs, adjusted OR 7.37; 95% CI, 6.71–8.10), use of tricyclic antidepressants (≥ 50 mg) (adjusted OR 5.49; 95% CI, 5.02–6.01), and concomitant use of ≥ 2 antidepressants (adjusted OR 5.52; 95% CI, 5.20–5.85). Conclusions: Long-term and potential high-risk use of antidepressants is widespread, and potential deprescribing indications (PDIs) are increasing, suggesting the need for a critical review of their ongoing use by clinicians. If deemed necessary, future deprescribing interventions may use the criteria applied here for identification of patients with PDIs and for evaluating intervention effectiveness.
AB - Background: Antidepressants have a pivotal role in the treatment of many psychiatric disorders, but there are concerns about long-term use and adverse effects. The objectives of this study were (1) to examine time trends in antidepressant use, (2) to estimate the prevalence of long-term and potential high-risk antidepressant use, and (3) to examine patient characteristics associated with potential deprescribing indications (PDIs) (i.e., simultaneous long-term and potential high-risk antidepressant use). Methods: Repeated population-based cross-sectional study for all 609,299 people aged ≥ 18 years resident in the Tayside or Fife regions of Scotland. The prevalence of antidepressant use was examined on June 30th (index date) of each year from 2012 to 2019, while the prevalence of long-term and potential high-risk use as well as PDIs was assessed and compared on the same dates in 2012 and 2019. Binary logistic regression modeling was used to examine patient characteristics associated with PDIs. Results: Antidepressant use increased by 27% from 12.0 to 15.3% among adult residents between 2012 and 2019. While the proportion of antidepressants users dispensed ≥ 1 antidepressant for > 2 years increased from 54.3 to 61.9% between 2012 and 2019, the proportion of antidepressant users triggering ≥ 1 indicator of potential high-risk use decreased slightly from 37.9 to 34.7%. In 2019, potential high-risk use most commonly related to indicators targeting fall risk (16.0%), cardiovascular risks (14.1%), insomnia (10.6%), and risk of orthostatic hypotension (8.6%). More than 1 in 4 (25.8%) antidepressant users had PDIs. The main risk factors associated with PDIs included increasing age (65–79, adjusted OR 14.12; 95% CI, 13.15–15.17), increasing number of drugs taken concomitantly (≥ 15 drugs, adjusted OR 7.37; 95% CI, 6.71–8.10), use of tricyclic antidepressants (≥ 50 mg) (adjusted OR 5.49; 95% CI, 5.02–6.01), and concomitant use of ≥ 2 antidepressants (adjusted OR 5.52; 95% CI, 5.20–5.85). Conclusions: Long-term and potential high-risk use of antidepressants is widespread, and potential deprescribing indications (PDIs) are increasing, suggesting the need for a critical review of their ongoing use by clinicians. If deemed necessary, future deprescribing interventions may use the criteria applied here for identification of patients with PDIs and for evaluating intervention effectiveness.
KW - Adverse drug events
KW - Antidepressants
KW - Deprescribing
KW - Long-term use
UR - http://www.scopus.com/inward/record.url?scp=85204071389&partnerID=8YFLogxK
U2 - 10.1186/s12916-024-03584-9
DO - 10.1186/s12916-024-03584-9
M3 - Article
C2 - 39256761
AN - SCOPUS:85204071389
SN - 1741-7015
VL - 22
JO - BMC Medicine
JF - BMC Medicine
M1 - 378
ER -